Contribution of Oncology Pharmacists in Cancer Care: A Need for Quality
Care

Kala   Bahadur   Rawal; Uday   Venkat   Mateti; Vijith      Shetty; Shashidhara   Chakrachodi   Shastry; Juno   Jerold   Joel; Shraddha      Shetty

doi:10.2174/1573404818666220113124438

Abstract

Cancer is known as a disease with a high morbidity and mortality rate. There are several short-term and long-term complications of cancer, leading to poor quality of life. Cancer in advanced stage and malignant tumors requiring a multisystem involvement makes the treatment challenging. The diverse health impact of cancer requires a multidisciplinary approach for treatment. The oncology pharmacy has facilitated a revolutionary approach for preparing and training specialised pharmacists to deal with a variety of health challenges faced by cancer patients. Oncology pharmacists or oncopharmacists are the experts in designing drug therapy and individualizing it in accordance with the requirements. The conventional and novel role of pharmacists in clinical pharmacy practice is documented to positively impact the health of cancer patients, including cancer survivors. Hence, this review tries to summarize the potential role of oncopharmacists.

Keywords: Cancer care, specialized pharmacist, clinical practice, evidence-based care, oncology pharmacist, therapy.

Graphical Abstract

[1]
What is cancer?  Available from: https://www.cancer.net/navigating-cancer-care/cancer-basics/what-cancer (Accessed 20 February 2021).

[2]
Cancer stat facts: Cancer of any site.  Available from: https://seer.cancer.gov/statfacts/html/all.html (Accessed 20 February 2021).

[3]
Mathur P, Sathishkumar K, Chaturvedi M, et al. Cancer statistics, 2020: Report from National Cancer Registry Programme, India. JCO Glob Oncol  2020; 6(6): 1063-75.
 [http://dx.doi.org/10.1200/GO.20.00122] [PMID: 32673076]

[4]
Takiar R, Jayant K. A model approach to calculate cancer prevalence from 5 year survival data for selected cancer sites in India. Asian Pac J Cancer Prev  2013; 14(11): 6899-903.
 [http://dx.doi.org/10.7314/APJCP.2013.14.11.6899] [PMID: 24377623]

[5]
Holle LM, Harris CS, Chan A, et al. Pharmacists’ roles in oncology pharmacy services: Results of a global survey. J Oncol Pharm Pract  2017; 23(3): 185-94.
 [http://dx.doi.org/10.1177/1078155216629827] [PMID: 26854267]

[6]
Ma C. Role of pharmacists in optimizing the use of anticancer drugs in the clinical setting. Integr Pharm Res Pract  2014; 3: 11-24.
 [http://dx.doi.org/10.2147/IPRP.S40428]

[7]
Duarte NC, Barbosa CR, Tavares MG, Dias LP, Souza RN, Moriel P. Clinical oncology pharmacist: Effective contribution to patient safety. J Oncol Pharm Pract  2019; 25(7): 1665-74.
 [http://dx.doi.org/10.1177/1078155218807748] [PMID: 30348073]

[8]
Pharmacist role in patient safety. 2019. Available from: https://psnet.ahrq.gov/perspective/pharmacist-role-patient-safety (Accessed 11 January 2021).

[9]
Gnjidic D, Hilmer SN, Blyth FM, et al. Polypharmacy cutoff and outcomes: Five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol  2012; 65(9): 989-95.
 [http://dx.doi.org/10.1016/j.jclinepi.2012.02.018] [PMID: 22742913]

[10]
Turner JP, Shakib S, Singhal N, et al. Prevalence and factors associated with polypharmacy in older people with cancer. Support Care Cancer  2014; 22(7): 1727-34.
 [http://dx.doi.org/10.1007/s00520-014-2171-x] [PMID: 24584682]

[11]
Nandakumar UP, Joel JJ. Oncopharmacists: The game changers in cancer therapy. J Young Pharmacists  2020; 12(1): 15-7.
 [http://dx.doi.org/10.5530/jyp.2020.12.4]

[12]
Patient safety definition from WHO.  Available from: https://www.who.int/teams/integrated-health-services/patient-safety/about (Accessed 10 February 2021).

[13]
Tezcan S, İzzettin FV, Sancar M, Turhal NS, Yumuk PF. Role of clinical oncology pharmacist in determination of pharmaceutical care needs in patients with colorectal cancer. Eur J Hosp Pharm Sci Pract  2018; 25(e1): e17-20.
 [http://dx.doi.org/10.1136/ejhpharm-2016-001188] [PMID: 31157061]

[14]
Roy D, Shanfar I, Shenoy P, Chand S, Nandakumar UP, Bharathraj KC. Drug-related problems among chronic kidney disease patients: A clinical pharmacist led study. Int J Pharm Res  2020; 12(4): 79-84.

[15]
Mansur JM. Medication safety systems and the important role of pharmacists. Drugs Aging  2016; 33(3): 213-21.
 [http://dx.doi.org/10.1007/s40266-016-0358-1] [PMID: 26932714]

[16]
Bertsch NS, Bindler RJ, Wilson PL, Kim AP, Ward B. Medication therapy management for patients receiving oral chemotherapy agents at a community oncology center: A pilot study. Hosp Pharm  2016; 51(9): 721-9.
 [http://dx.doi.org/10.1310/hpj5109-721] [PMID: 27803501]

[17]
Lukali V, Michelo C. Factors associated with irrational drug use at a District Hospital in Zambia: Patient record-based observations. Med J Zambia  2015; 42(1): 25-30.

[18]
Holle LM, Boehnke Michaud L. Oncology pharmacists in health care delivery: Vital members of the cancer care team. J Oncol Pract  2014; 10(3): e142-5.
 [http://dx.doi.org/10.1200/JOP.2013.001257] [PMID: 24618076]

[19]
Walter C, Mellor JD, Rice C, et al. Impact of a specialist clinical cancer pharmacist at a multidisciplinary lung cancer clinic. Asia Pac J Clin Oncol  2016; 12(3): e367-74.
 [http://dx.doi.org/10.1111/ajco.12267] [PMID: 25227909]

[20]
Chung C, Collins A, Cui N. Development and implementation of an interdisciplinary oncology program in a community hospital. Am J Health Syst Pharm  2011; 68(18): 1740-7.
 [http://dx.doi.org/10.2146/ajhp100626] [PMID: 21880891]

[21]
Birand N, Boşnak AS, Diker Ö, Abdikarim A, Başgut B. The role of the pharmacist in improving medication beliefs and adherence in cancer patients. J Oncol Pharm Pract  2019; 25(8): 1916-26.
 [http://dx.doi.org/10.1177/1078155219831377] [PMID: 30786821]

[22]
Moss A, Won K, Weber L. Medication therapy management in the outpatient cancer center. Hematol Oncol Pharm  2012; 2(3): 103-7.

[23]
Lin Q, Wang G, Ma G, Shen Q. The role of pharmaceutical care in the oncology department. Eur J Hosp Pharm Sci Pract  2015; 22: 128-31.
 [http://dx.doi.org/10.1136/ejhpharm-2014-000591]

[24]
Dang CC, Amiruddin M, Lai SS, Low CF, Chan SY. An emerging role of pharmacist in pre-chemotherapy counseling among breast cancer patients. Indian J Pharm Sci  2017; 79(2): 294-302.
 [http://dx.doi.org/10.4172/pharmaceutical-sciences.1000228]

[25]
Blaschke TF, Osterberg L, Vrijens B, Urquhart J. Adherence to medications: Insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu Rev Pharmacol Toxicol  2012; 52: 275-301.
 [http://dx.doi.org/10.1146/annurev-pharmtox-011711-113247] [PMID: 21942628]

[26]
Ramesh A, Rajanandh MG, Thanmayee S, Salagha MG, Suresh S, Srinivas GKS. Impact of patient counseling on medication adherence, beliefs and satisfaction about oral chemotherapies in patients with metastatic cancer at a super specialty hospital. J Cancer Res  2015; 11(3): 128-35.

[27]
Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin  2009; 59(1): 56-66.
 [http://dx.doi.org/10.3322/caac.20004] [PMID: 19147869]

[28]
The Role of hematology/oncology pharmacists. Hematology/oncology pharmacist association 2014. Available from: https://www.hoparx.org/images/hopa/advocacy/Access-to-pharmacists-care/HOPA_About_Hem_Onc_Pharmacist_Issue_Brief_FINAL.pdf (Accessed 21 February 2021).

[29]
Hébuterne X, Lemarié E, Michallet M, de Montreuil CB, Schneider SM, Goldwasser F. Prevalence of malnutrition and current use of nutrition support in patients with cancer. J Parenter Enteral Nutr  2014; 38(2): 196-204.
 [http://dx.doi.org/10.1177/0148607113502674] [PMID: 24748626]

[30]
de Las Peñas R, Majem M, Perez-Altozano J, et al. SEOM clinical guidelines on nutrition in cancer patients (2018). Clin Transl Oncol  2019; 21(1): 87-93.
 [http://dx.doi.org/10.1007/s12094-018-02009-3] [PMID: 30617923]

[31]
Caccialanza R, Pedrazzoli P, Cereda E, et al. Nutritional support in cancer patients: A position paper from the Italian Society of Medical Oncology (AIOM) and the Italian Society of Artificial Nutrition and Metabolism (SINPE). J Cancer  2016; 7(2): 131-5.
 [http://dx.doi.org/10.7150/jca.13818] [PMID: 26819635]

[32]
Palliative care in cancer. National institute of cancer.  Available from: https://www.cancer.gov/about-cancer/advanced-cancer/care-choices/palliative-care-fact-sheet#what-is-palliative-care (Accessed 05 February 2021).

[33]
Crul M, Oosterhof P. The oncology pharmacist as part of the palliative treatment team. Int J Pharm Pract  2020; 28(1): 92-6.
 [http://dx.doi.org/10.1111/ijpp.12583] [PMID: 31576620]

[34]
Colombo LRP, Aguiar PM, Lima TM, Storpirtis S. The effects of pharmacist interventions on adult outpatients with cancer: A systematic review. J Clin Pharm Ther  2017; 42(4): 414-24.
 [http://dx.doi.org/10.1111/jcpt.12562] [PMID: 28556392]

[35]
Eades CE, Ferguson JS, O’Carroll RE. Public health in community pharmacy: A systematic review of pharmacist and consumer views. BMC Public Health  2011; 11: 582.
 [http://dx.doi.org/10.1186/1471-2458-11-582] [PMID: 21777456]

[36]
Patel H, Gurumurthy P. Implementation and evaluation of medicine and therapeutic information service by clinical pharmacists in oncology care setting. J Oncol Pharm Pract  2019; 25(1): 60-7.
 [http://dx.doi.org/10.1177/1078155217727141] [PMID: 28841101]

[37]
Dowd M. The role of specialty pharmacy in medication adherence. 2016. Available from: https://www.pharmacytimes.com/view/the-role-of-specialty-pharmacy-in-medication-adherence (Accessed 15 March 2021).

[38]
Tailored pharmacy-based interventions to improve medication adherence.  Available from: https://www.cdc.gov/dhdsp/pubs/medication-adherence.htm (Accessed 15 March 2021).

[39]
Tanaka K, Hori A, Tachi T, et al. Impact of pharmacist counseling on reducing instances of adverse events that can affect the quality of life of chemotherapy outpatients with breast cancer. J Pharm Health Care Sci  2018; 4: 9.
 [http://dx.doi.org/10.1186/s40780-018-0105-3] [PMID: 29736254]

[40]
Farrag DK, Sabri NA, Tawfik AS, Shaheen SM. Evaluation of the clinical effect of pharmacist intervention. Eur J Oncol Pharm  2020; 3(1): e23.
 [http://dx.doi.org/10.1097/OP9.0000000000000023]

[41]
North RT, Harvey VJ, Cox LC, Ryan SN. Medical resource utilization for administration of trastuzumab in a New Zealand oncology outpatient setting: A time and motion study. Clinicoecon Outcomes Res  2015; 7: 423-30.
 [PMID: 26251623]

[42]
Mackler E, Segal EM, Muluneh B, Jeffers K, Carmichael J. 2018 Hematology/oncology pharmacist association best practices for the management of oral oncolytic therapy: Pharmacy practice standard. J Oncol Pract  2019; 15(4): e346-55.
 [http://dx.doi.org/10.1200/JOP.18.00581] [PMID: 30860937]

[43]
Vinks TH, de Koning FH, de Lange TM, Egberts TC. Identification of potential drug-related problems in the elderly: The role of the community pharmacist. Pharm World Sci  2006; 28(1): 33-8.
 [http://dx.doi.org/10.1007/s11096-005-4213-4] [PMID: 16703267]

[44]
Pullinger W, Franklin BD. Pharmacists’ documentation in patients’ hospital health records: Issues and educational implications. Int J Pharm Pract  2010; 18(2): 108-15.
 [http://dx.doi.org/10.1211/ijpp.18.02.0006] [PMID: 20441120]

[45]
Matzke GR. Pharmacist participation in health policy development. Am J Health Syst Pharm  2016; 73(3): 107.
 [http://dx.doi.org/10.2146/ajhp150731] [PMID: 26796902]

[46]
Martini N, Basdew K, Kammona A, et al. Pharmacists’ views on and experiences with bowel cancer screening kits in Auckland, New Zealand. Int J Pharm Pract  2014; 22(4): 257-64.
 [http://dx.doi.org/10.1111/ijpp.12074] [PMID: 24118479]

[47]
Chow MC, Chambers P, Singleton G, et al. Global changes to the chemotherapy service during the covid-19 pandemic. J Oncol Pharm Pract  2021; 27(5): 1073-9.
 [http://dx.doi.org/10.1177/10781552211015767] [PMID: 33983080]

[48]
Visacri MB, Figueiredo IV, Lima TM. Role of pharmacist during the COVID-19 pandemic: A scoping review. Res Social Adm Pharm  2021; 17(1): 1799-806.
 [http://dx.doi.org/10.1016/j.sapharm.2020.07.003] [PMID: 33317760]

[49]
Pourroy B, Tournamille JF, Bardin C, et al. Providing oncology pharmacy services during the coronavirus pandemic: French Society for Oncology Pharmacy (Société Francaise de Pharmacie Oncologique [SFPO]) Guidelines. JCO Oncol Pract  2020; 16(11): e1282-90.
 [http://dx.doi.org/10.1200/OP.20.00295] [PMID: 32539650]

[50]
Wang D, Liu Y, Zeng F, et al. Evaluation of the role and usefulness of clinical pharmacists at the Fangcang Hospital during COVID-19 outbreak. Int J Clin Pract  2021; 75(8): e14271.
 [http://dx.doi.org/10.1111/ijcp.14271] [PMID: 33894041]

Rights & Permissions Print Cite

Article Metrics

4

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/1573404818666220113124438	Print ISSN 1573-4048
Publisher Name Bentham Science Publisher	Online ISSN 1875-6581

Current Women`s Health Reviews

Contribution of Oncology Pharmacists in Cancer Care: A Need for Quality Care

Abstract Play Pause

Graphical Abstract

Abstract